Radiotherapy Market Analysis

The global radiotherapy market represents a critical and rapidly expanding segment of the oncology landscape, underpinned by the rising worldwide cancer burden and the essential role of radiation therapy in curative and palliative treatment. The International Agency for Research on Cancer (IARC) estimates approximately 20 million new cancer cases were diagnosed globally in 2025, a figure projected to rise to 22.6 million by 2030 and 34.4 million by 2050. Cancer remains the second leading cause of mortality worldwide, with an estimated 10 million deaths annually. Approximately 50% of all cancer patients have an indication for radiotherapy at some point during their treatment journey, making it a cornerstone of modern oncology. The World Health Organization (WHO) recommends that 50-60% of cancer patients should receive radiotherapy, yet global access remains highly inequitable, with nearly one-third of countries lacking adequate radiotherapy services. According to the research report, "Global Radiotherapy Market Outlook, 2031," published by Actual Market Research, the Global Radiotherapy market was valued at more than USD 8.98 Billion in 2025, and expected to reach a market size of more than USD 14.07 Billion by 2031 with the CAGR of 7.97% from 2026-2031. This growth trajectory is driven by the expanding cancer patient population, technological advancements in treatment delivery, and significant government and private sector investment in healthcare infrastructure. North America and Europe currently represent the largest regional markets, while Asia-Pacific is the fastest-growing region, driven by rapid infrastructure expansion in China, India, and Southeast Asia. The global installed base of teletherapy machines is estimated at approximately 12,000–15,000 units as of 2025, with 60–65% being high-energy linear accelerators (LINACs). External Beam Radiotherapy (EBRT) represents the largest therapy segment globally, driven by the extensive installed base of linear accelerators and the clinical dominance of advanced techniques including IMRT, IGRT, VMAT, and SBRT. Systemic radiotherapy is the fastest-growing therapy segment, fueled by the emergence of novel radiopharmaceuticals and targeted radionuclide therapies. Radiotherapy systems and equipment hold the largest offering segment share, while software and services represent the fastest-growing segment.

Breast cancer is the largest application segment, driven by high global incidence rates, while central nervous system and brain cancers are the fastest-growing. Hospitals and integrated cancer centres dominate end-use spending, with academic and research institutions growing fastest. The IAEA's Rays of Hope initiative continues to expand access to radiotherapy in low- and middle-income countries, with 12 Anchor Centres now established across Africa, Asia, Europe, and Latin America. .

Market Dynamic

RadiotherapySegmentation

External Beam Radiotherapy (EBRT) is the largest therapy segment because the extensive installed base of linear accelerators and the clinical dominance of advanced techniques including IMRT, IGRT, VMAT, and SBRT make it the modality of choice for a broad spectrum of malignancies worldwide.

External Beam Radiotherapy (EBRT) represents the largest therapy segment in the global radiotherapy market, driven by the extensive installed base of linear accelerators and the clinical dominance of advanced techniques. EBRT is the modality of choice for a broad spectrum of malignancies due to its effectiveness, non-invasiveness, and well-established evidence base. The global installed base of teletherapy machines is estimated at approximately 12,000–15,000 units as of 2025, with 60–65% being high-energy linear accelerators. Premium-feature segments machines equipped with IGRT, SRS, and MR-guided platforms command 50–60% of new-system revenue, with average selling prices ranging from USD 1.5 million to USD 4.5 million depending on configuration. Major equipment suppliers including Varian Medical Systems (a division of Siemens Healthineers), Elekta, and Accuray dominate the EBRT segment. Technology upgrade cycles are shortening from 12–15 years to 8–12 years as hospitals adopt hypofractionation, MR-LINACs, and real-time adaptive radiotherapy.

Systemic Radiotherapy is the fastest-growing therapy segment because the emergence of novel radiopharmaceuticals and targeted radionuclide therapies is creating new treatment options for specific malignancies, supported by substantial research funding and regulatory frameworks.

Systemic Radiotherapy represents the fastest-growing therapy segment in the global radiotherapy market, fueled by the emergence of novel radiopharmaceuticals and targeted radionuclide therapies for treating metastatic prostate cancer, neuroendocrine tumours, and certain lymphomas. The IAEA is supporting the development of nuclear medicine and theranostics capabilities globally, including through its technical cooperation programme and the Rays of Hope initiative. The global radiopharmaceutical market is expanding rapidly, with significant investment in research and development from both pharmaceutical companies and government agencies. This segment is a focal point for innovation and represents a significant area for future market expansion.

Radiotherapy Systems/Equipment is the largest offering segment because high capital costs, continuous technological innovation, and the replacement of aging equipment drive substantial investment in treatment delivery systems globally.

Radiotherapy Systems/Equipment represents the largest offering segment in the global radiotherapy market, driven by the high capital cost of advanced treatment delivery systems. This includes linear accelerators, proton therapy systems, gamma knives, robotic radiosurgery platforms, and brachytherapy afterloaders. Growth in this segment is sustained by continuous technological innovation, the replacement of aging equipment across the installed base, and the expansion of new cancer centres globally. Premium-feature segments command 50–60% of new-system revenue. Annual replacement demand from ageing equipment accounts for 40–50% of new unit sales. Major suppliers include Varian Medical Systems (Siemens Healthineers), Elekta, Accuray, and IBA (proton therapy). Domestic production in China and India is expanding, with Chinese manufacturers now supplying an estimated 25–30% of new teletherapy units installed in Asia-Pacific.

Software & Services is the fastest-growing offering segment because the increasing digitalisation of radiation oncology, workforce shortages, and the need for comprehensive lifecycle management are driving demand for advanced software solutions and maintenance services.

Software & Services represents the fastest-growing offering segment in the global radiotherapy market, reflecting the increasing digitalisation of radiation oncology. The software component includes advanced treatment planning systems, AI-powered contouring and dose optimisation tools, image registration and fusion platforms, and patient data management systems. The services component encompasses installation, comprehensive maintenance, clinical training, physics support, cybersecurity updates, and remote technical support. After-sales service and consumables (replacement parts, beam-shaping multileaf collimators, imaging detectors, and software upgrades) contribute 30–35% of total market revenue and are growing faster than new-system sales as the installed base ages. The trend toward outsourcing maintenance and support services, driven by workforce constraints and the growing complexity of equipment, is a key driver for this segment.

Proton Beam Therapy is the fastest-growing technology segment because the expansion of proton therapy infrastructure globally, supported by clinical evidence and investment, is driving significant adoption of this advanced modality.

Proton Beam Therapy represents the fastest-growing technology segment in the global radiotherapy market, reflecting the expansion of proton therapy infrastructure worldwide. The global proton therapy market is estimated at approximately USD 2.18 billion in 2025, with a projected CAGR of 8.75% through 2034. Proton therapy offers significant advantages for paediatric cancers, brain tumours, and head and neck cancers by reducing dose to surrounding healthy tissues. Rotating proton therapy systems dominated the market in 2025. The segment is driven by rising global cancer incidence and increasing demand for highly precise, minimally invasive treatment options. Major suppliers include IBA and Varian Medical Systems. Significant investments are underway across North America, Europe, Asia-Pacific, and the Middle East.

Other Technology is the largest technology segment because it encompasses a broad range of established modalities including IMRT, IGRT, SRS, 3D-CRT, and VMAT, which collectively represent the majority of radiotherapy treatments delivered globally.

Other Technology represents the largest technology segment in the global radiotherapy market, encompassing a broad range of established modalities. This includes Image-Guided Radiotherapy (IGRT), Intensity-Modulated Radiotherapy (IMRT), Stereotactic Radiosurgery (SRS), 3D-Conformal Radiotherapy (3D-CRT), and Volumetric Modulated Arc Therapy (VMAT). IMRT has become a standard of care globally, with high adoption rates in high-income countries and growing adoption in emerging economies. IGRT is a foundational technology enabling precise targeting through imaging during treatment. VMAT has gained significant adoption due to its ability to reduce treatment times. The widespread availability of these technologies in major cancer centres globally is supported by strong reimbursement frameworks in high-income countries and growing investment in emerging markets.

Breast Cancer is the largest application segment because high global incidence rates and the well-established role of radiotherapy in both breast-conserving therapy and post-mastectomy settings sustain steady demand for treatment equipment and planning software worldwide.

Breast Cancer represents the largest application segment in the global radiotherapy market, driven by the high global incidence of breast cancer and the well-established role of radiotherapy in treatment. Breast cancer is the most frequently diagnosed cancer among women globally, sustaining steady demand for treatment equipment and planning software. Techniques including accelerated partial breast irradiation, hypofractionated whole-breast irradiation, and deep inspiration breath-hold are standard practice across the globe. The expansion of screening programmes in both high-income and emerging economies has led to earlier detection, further driving demand for radiotherapy as a component of multidisciplinary care. In LMICs, the need for breast cancer radiotherapy is particularly acute due to later stage at presentation.

Central Nervous System / Brain is the fastest-growing application because the use of stereotactic radiosurgery for brain metastases, the development of sophisticated MR-guided radiotherapy for high-grade gliomas, and updated clinical guidelines are driving significant investment in advanced equipment and software globally.

Central Nervous System / Brain represents the fastest-growing application in the global radiotherapy market, driven by the use of stereotactic radiosurgery for brain metastases, the development of sophisticated MR-guided radiotherapy for high-grade gliomas, and the publication of updated clinical guidelines. The technological complexity and precision requirements of CNS radiotherapy drive significant investment in advanced equipment and software. Dedicated systems including Gamma Knife and Cyberknife are available across major centres globally. Proton therapy offers significant advantages for paediatric brain tumours and is driving investment in this area. The global proton therapy market identifies brain tumours as a key application segment.

Hospitals & Integrated Cancer Centres are the largest end-user segment because these institutions provide comprehensive, multidisciplinary cancer care and possess the infrastructure, capital resources, and clinical expertise to invest in the full range of advanced radiotherapy technologies globally.

Hospitals & Integrated Cancer Centres represent the largest end-user segment in the global radiotherapy market, as these institutions provide comprehensive, multidisciplinary cancer care and possess the infrastructure, capital resources, and clinical expertise to invest in the full range of advanced radiotherapy technologies. These organisations often serve as regional referral centres, manage complex and high-acuity cases, and operate the most diverse equipment fleets including multiple LINACs, proton systems, and brachytherapy programmes. The hospitals segment is projected to grow at a significant rate. In emerging economies, hospitals are the primary recipients of government investment in radiotherapy infrastructure.

Academic/Research Institutions are the fastest-growing end-user segment because their central role in advancing the field through clinical trials, technology validation, and workforce training drives high adoption rates of innovative technologies globally.

Academic/Research Institutions represent the fastest-growing end-user segment in the global radiotherapy market, reflecting their central role in advancing the field. They conduct clinical trials, develop and test new technologies including FLASH radiotherapy and novel radiopharmaceuticals, validate emerging treatment protocols, and train the next generation of radiation oncologists, medical physicists, and therapists. The IAEA's Rays of Hope Anchor Centres, selected for their clinical excellence, education programmes, and research capacity, serve as critical hubs of expertise and training. Their high adoption rate of innovative technologies makes them a key driver of market growth and a bellwether for broader clinical adoption.

Radiotherapy Market Regional Insights

North America dominates the global radiotherapy market because of its advanced healthcare infrastructure, high healthcare expenditure, extensive hospital network, and stringent regulatory requirements that support comprehensive radiotherapy programmes and rapid technology adoption.

North America represents the largest regional radiotherapy market, holding a market share exceeding 35% globally. The United States is the dominant country within the region, supported by over 6,100 hospitals, extensive diagnostic imaging networks, and a large installed base of linear accelerators and proton therapy centres (over 40 operating centres). National health spending in the United States is projected to rise from USD 4.8 trillion in 2023 to USD 7.7 trillion by 2032, highlighting the scale of healthcare investment. Canada represents a mature market with a well-established publicly funded healthcare system. Mexico represents an emerging opportunity with rising private healthcare investment and gradual regulatory modernisation through COFEPRIS. North America is expected to remain the dominant regional market through the forecast period.
Europe represents a mature but dynamic market with significant investment in infrastructure modernisation across Western, Southern, and Eastern European countries, supported by strong research funding and professional networks.

Europe represents the second-largest regional radiotherapy market, accounting for approximately 25–30% of global unit demand. Germany, France, and the United Kingdom are the primary contributors to regional spending, supported by their advanced healthcare systems and large installed bases. The UK's NHS Supply Chain has procured 28 new LINAC systems in 2025/26, delivering savings of £21.8 million. Italy's National Recovery and Resilience Plan (PNRR) has funded 62 linear accelerators valued at approximately €130 million. Spain is advancing deployment of its proton therapy network. The European Union's Horizon Europe programme has allocated USD 5.3 billion to health programmes for 2021-2027, funding research on advanced radiotherapy technologies.
Asia-Pacific is the fastest-growing regional market because rapid economic development, large and aging populations, and substantial government investment in healthcare infrastructure are driving significant expansion of radiotherapy capacity across the region.

Asia-Pacific represents the fastest-growing regional radiotherapy market, contributing 25–30% of global unit demand. China and India are the primary growth engines. China's National Health Commission has approved 42 hospitals to configure heavy-ion proton radiotherapy systems as of December 2025. India faces a significant infrastructure deficit, with only 794 megavoltage machines for a population of 1.45 billion a shortfall of approximately 45% from the minimum required standard. Japan represents a mature market with advanced technology adoption, with the Ministry of Health projecting a 24% increase in radiotherapy demand through 2040. South Korea is emerging as a leader in advanced particle therapy, with health insurance now covering MRI-guided radiotherapy. Australia has added new MBS items for proton beam therapy. Domestic production in China and India is expanding, with Chinese manufacturers now supplying an estimated 25–30% of new teletherapy units installed in the region.
The Middle East and Africa represent diverse regional markets with significant disparities in infrastructure, from advanced proton therapy centres in GCC countries to severe equipment shortages in sub-Saharan Africa, supported by international initiatives such as the IAEA's Rays of Hope programme.

The Middle East and Africa region represents a diverse market with significant disparities in infrastructure and access. Saudi Arabia has launched the first proton therapy centre in the Middle East at King Fahad Medical City. The UAE is developing the region's first heavy-ion therapy facility and proton therapy centre. Egypt is installing its first proton beam therapy facility. However, in Africa, over 20 countries do not have a single radiotherapy machine. Nigeria, with over 223 million people, has only 15 radiotherapy machines. South Africa faces a backlog of nearly 3,000 patients awaiting radiation oncology treatment. The IAEA's Rays of Hope initiative is expanding access through equipment delivery, training, and Anchor Centre designation in Algeria, Egypt, Jordan, Morocco, Qatar, and South Africa.
South America represents an emerging regional market with significant growth potential, driven by substantial government investment in radiotherapy infrastructure modernisation, particularly in Brazil and Argentina.

South America represents an emerging regional market with significant growth potential. Brazil is the largest market, with INCA estimating approximately 781,000 new cancer cases per year in 2026–2028. The Brazilian government has delivered 22 linear accelerators in 2025, with plans to acquire 121 by 2026. Argentina has announced a significant investment for the Hospital Garrahan, including a paediatric linear accelerator. Colombia faces a deficit of 31 LINACs from IAEA standards, with 12 states lacking any LINACs. Chile requires 68 LINACs versus 41 operative. The IAEA and PAHO continue to support capacity building across the region.